{
  "guideline": {
    "id": "PA166104987",
    "name": "Annotation of DPWG Guideline for lansoprazole and CYP2C19",
    "source": "DPWG",
    "version": 29,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104987",
    "relatedChemicals": [
      {
        "id": "PA450180",
        "name": "lansoprazole",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA124",
        "name": "cytochrome P450 family 2 subfamily C member 19",
        "symbol": "CYP2C19"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166299062",
      "name": "Recommendation PA166299062",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA450180",
          "name": "lansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061425,
        "html": "<p>The guideline does not provide a recommendation for lansoprazole in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on lansoprazole."
      ],
      "lookupKey": {
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299061",
      "name": "Recommendation PA166299061",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450180",
          "name": "lansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061424,
        "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "The higher plasma concentration of lansoprazole results in an increase in the therapeutic effectiveness, without an increase in the incidence of side effects."
      ],
      "lookupKey": {
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299060",
      "name": "Recommendation PA166299060",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450180",
          "name": "lansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061423,
        "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "The higher plasma concentration of lansoprazole results in an increase in the therapeutic effectiveness, without an increase in the incidence of side effects."
      ],
      "lookupKey": {
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299063",
      "name": "Recommendation PA166299063",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA450180",
          "name": "lansoprazole",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061426,
        "html": "<p>For Helicobacter pylori ERADICATION THERAPY: 1. Use a 4-fold higher dose. 2. Advise the patient to contact their doctor if symptoms of dyspepsia persist.\nOTHER INDICATIONS: 1. Be alert to reduced effectiveness. 2. If necessary, use a 4-fold higher dose. 3. Advise the patient to report persisting symptoms of dyspepsia.</p>\n"
      },
      "implications": [
        "The genetic variation may reduce lansoprazole plasma concentrations and therefore lansoprazole effectiveness."
      ],
      "lookupKey": {
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011
    }
  ],
  "version": "2023-12-19-10-38"
}